Abstract
Original language | English |
---|---|
Journal | Molecular Therapy |
Early online date | 2023 |
DOIs | |
Publication status | E-pub ahead of print - 2023 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
MicroRNA-216a is essential for cardiac angiogenesis. / Juni, Rio P.; Kocken, Jordy M. M.; Abreu, Ricardo C. et al.
In: Molecular Therapy, 2023.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - MicroRNA-216a is essential for cardiac angiogenesis
AU - Juni, Rio P.
AU - Kocken, Jordy M. M.
AU - Abreu, Ricardo C.
AU - Ottaviani, Lara
AU - Davalan, Tim
AU - Duygu, Burcu
AU - Poels, Ella M.
AU - Vasilevich, Aliaksei
AU - Hegenbarth, Jana C.
AU - Appari, Mahesh
AU - Bitsch, Nicole
AU - Olieslagers, Serve
AU - Schrijvers, Dorien M.
AU - Stoll, Monika
AU - Heineke, Joerg
AU - de Boer, Jan
AU - de Windt, Leon J.
AU - da Costa Martins, Paula A.
N1 - Funding Information: We acknowledge Genoway (Lyon, France) for helping with the strategy and generation of the miR-216a KO mice. Funding: A.V. acknowledges the financial support of the European Union's Seventh Framework (FP7/2007-2013) grant agreement 289720. J.D.B. acknowledges the financial support of the Dutch province of Limburg. L.D.W. acknowledges support from the Netherlands Cardiovascular Research Initiative and the Dutch Heart Foundation, the Netherlands. L.D.W. was further supported by grant 311549 from the European Research Council (ERC) and a VICI award 918-156-47 from The Netherlands Organization for Scientific Research (NWO). P.C.M. is supported by a MEERVOUD grant from The Netherlands Organization for Scientific Research (NWO), a Dutch CardioVascular Alliance (DCVA) awarded to the Phaedra consortium, as well as the Impulse Grant 2018 awarded to the Phaedra IMPACT consortium (CVON-2018-29), and is an Established Investigator of the Dutch Heart Foundation (NHS2015T066). P.C.M. and R.C.A. were further supported by the H2020 Twinning project RESETageing (GA 952266). J.M.M.K. was supported by a Dutch CardioVascular Alliance (DCVA) awarded to the Phaedra consortium as well as the Impulse Grant 2018 awarded to the Phaedra IMPACT consortium (CVON-2018-29). R.P.J. B.D. S.O. J.M.M.K. R.C.A. E.M.P. T.D. and P.A.d.C.M. performed northern blots, qRT-PCR, western blots experiments, and angiogenic functional assays. R.P.J. R.C.A. and A.V. performed the functional screening and respective validation. R.J.P. J.M.M.K. B.D. and M.A. performed primary cell isolations. R.J.P. D.M.S. and N.B. performed surgical procedures and echocardiography in mouse models. R.J.P. and J.M.M.K. performed histology in the different mouse models, the in situ hybridizations, and generated the luciferase reporter constructs used in the luciferase assays. R.J.P. T.D. and R.C.A. performed the photoacoustics combined with ultrasound analysis of the mouse models. L.O. J.C.H. and M.S. performed the sequencing and the bioinformatics analysis. P.A.d.C.M. and L.J.d.W. generated miR-216a gene-targeted mouse mice. J.D.B. and L.J.d.W. provided reagents, models or data, and critically reviewed the manuscript before submission. P.A.d.C.M. acquired funding for the study. L.d.W. and P.d.C.M. are cofounders of Mirabilis Therapeutics. Funding Information: We acknowledge Genoway (Lyon, France) for helping with the strategy and generation of the miR-216a KO mice. Funding: A.V. acknowledges the financial support of the European Union’s Seventh Framework ( FP7/2007-2013 ) grant agreement 289720 . J.D.B. acknowledges the financial support of the Dutch province of Limburg . L.D.W. acknowledges support from the Netherlands Cardiovascular Research Initiative and the Dutch Heart Foundation , the Netherlands. L.D.W. was further supported by grant 311549 from the European Research Council (ERC) and a VICI award 918-156-47 from The Netherlands Organization for Scientific Research ( NWO ). P.C.M. is supported by a MEERVOUD grant from The Netherlands Organization for Scientific Research ( NWO ), a Dutch CardioVascular Alliance ( DCVA ) awarded to the Phaedra consortium, as well as the Impulse Grant 2018 awarded to the Phaedra IMPACT consortium ( CVON-2018-29 ), and is an Established Investigator of the Dutch Heart Foundation ( NHS2015T066 ). P.C.M. and R.C.A. were further supported by the H2020 Twinning project RESETageing ( GA 952266 ). J.M.M.K. was supported by a Dutch CardioVascular Alliance ( DCVA ) awarded to the Phaedra consortium as well as the Impulse Grant 2018 awarded to the Phaedra IMPACT consortium ( CVON-2018-29 ). Publisher Copyright: © 2023 The Author(s)
PY - 2023
Y1 - 2023
N2 - While it is experimentally supported that impaired myocardial vascularization contributes to a mismatch between myocardial oxygen demand and supply, a mechanistic basis for disruption of coordinated tissue growth and angiogenesis in heart failure remains poorly understood. Silencing strategies that impair microRNA biogenesis have firmly implicated microRNAs in the regulation of angiogenesis, and individual microRNAs prove to be crucial in developmental or tumor angiogenesis. A high-throughput functional screening for the analysis of a whole-genome microRNA silencing library with regard to their phenotypic effect on endothelial cell proliferation as a key parameter, revealed several anti- and pro-proliferative microRNAs. Among those was miR-216a, a pro-angiogenic microRNA which is enriched in cardiac microvascular endothelial cells and reduced in expression under cardiac stress conditions. miR-216a null mice display dramatic cardiac phenotypes related to impaired myocardial vascularization and unbalanced autophagy and inflammation, supporting a model where microRNA regulation of microvascularization impacts the cardiac response to stress.
AB - While it is experimentally supported that impaired myocardial vascularization contributes to a mismatch between myocardial oxygen demand and supply, a mechanistic basis for disruption of coordinated tissue growth and angiogenesis in heart failure remains poorly understood. Silencing strategies that impair microRNA biogenesis have firmly implicated microRNAs in the regulation of angiogenesis, and individual microRNAs prove to be crucial in developmental or tumor angiogenesis. A high-throughput functional screening for the analysis of a whole-genome microRNA silencing library with regard to their phenotypic effect on endothelial cell proliferation as a key parameter, revealed several anti- and pro-proliferative microRNAs. Among those was miR-216a, a pro-angiogenic microRNA which is enriched in cardiac microvascular endothelial cells and reduced in expression under cardiac stress conditions. miR-216a null mice display dramatic cardiac phenotypes related to impaired myocardial vascularization and unbalanced autophagy and inflammation, supporting a model where microRNA regulation of microvascularization impacts the cardiac response to stress.
KW - angiogenesis
KW - autophagy
KW - cardiac remodeling
KW - endothelial cells
KW - heart failure
KW - microRNAs
UR - http://www.scopus.com/inward/record.url?scp=85153870231&partnerID=8YFLogxK
U2 - 10.1016/j.ymthe.2023.04.007
DO - 10.1016/j.ymthe.2023.04.007
M3 - Article
C2 - 37073128
SN - 1525-0016
JO - Molecular Therapy
JF - Molecular Therapy
ER -